TargetGenome polyprotein [2420-3010](Hepatitis C virus genotype 1b (isolate Con1) (HCV))
Gilead Pharmasset
US Patent
Gilead Pharmasset
US Patent
Affinity DataEC50: 274nMpH: 7.5 T: 2°CAssay Description:The HCV NS5B reaction was performed in a 20 μL mixture containing varying concentrations of the test compound, 1 μM of all four natural ribonuc...More data for this Ligand-Target Pair
TargetGenome polyprotein [2420-3010](Hepatitis C virus genotype 1b (isolate Con1) (HCV))
Gilead Pharmasset
US Patent
Gilead Pharmasset
US Patent
Affinity DataEC50: 310nMpH: 7.5 T: 2°CAssay Description:The HCV NS5B reaction was performed in a 20 μL mixture containing varying concentrations of the test compound, 1 μM of all four natural ribonuc...More data for this Ligand-Target Pair
TargetGenome polyprotein [2420-3010](Hepatitis C virus genotype 1b (isolate Con1) (HCV))
Gilead Pharmasset
US Patent
Gilead Pharmasset
US Patent
Affinity DataEC50: 390nMpH: 7.5 T: 2°CAssay Description:The HCV NS5B reaction was performed in a 20 μL mixture containing varying concentrations of the test compound, 1 μM of all four natural ribonuc...More data for this Ligand-Target Pair
TargetGenome polyprotein [2420-3010](Hepatitis C virus genotype 1b (isolate Con1) (HCV))
Gilead Pharmasset
US Patent
Gilead Pharmasset
US Patent
Affinity DataEC50: 450nMpH: 7.5 T: 2°CAssay Description:The HCV NS5B reaction was performed in a 20 μL mixture containing varying concentrations of the test compound, 1 μM of all four natural ribonuc...More data for this Ligand-Target Pair
TargetGenome polyprotein [2420-3010](Hepatitis C virus genotype 1b (isolate Con1) (HCV))
Gilead Pharmasset
US Patent
Gilead Pharmasset
US Patent
Affinity DataEC50: 566nMpH: 7.5 T: 2°CAssay Description:The HCV NS5B reaction was performed in a 20 μL mixture containing varying concentrations of the test compound, 1 μM of all four natural ribonuc...More data for this Ligand-Target Pair
TargetGenome polyprotein [2420-3010](Hepatitis C virus genotype 1b (isolate Con1) (HCV))
Gilead Pharmasset
US Patent
Gilead Pharmasset
US Patent
Affinity DataEC50: 670nMpH: 7.5 T: 2°CAssay Description:The HCV NS5B reaction was performed in a 20 μL mixture containing varying concentrations of the test compound, 1 μM of all four natural ribonuc...More data for this Ligand-Target Pair
TargetGenome polyprotein [2420-3010](Hepatitis C virus genotype 1b (isolate Con1) (HCV))
Gilead Pharmasset
US Patent
Gilead Pharmasset
US Patent
Affinity DataEC50: 857nMpH: 7.5 T: 2°CAssay Description:The HCV NS5B reaction was performed in a 20 μL mixture containing varying concentrations of the test compound, 1 μM of all four natural ribonuc...More data for this Ligand-Target Pair
TargetGenome polyprotein [2420-3010](Hepatitis C virus genotype 1b (isolate BK) (HCV))
Merck Sharp & Dohme
US Patent
Merck Sharp & Dohme
US Patent
Affinity DataEC50: 1.30E+3nMT: 2°CAssay Description:To measure cell-based anti-HCV activity of selected compounds of the present invention, replicon cells were seeded at 5000 cells/well in 96-well coll...More data for this Ligand-Target Pair
TargetGenome polyprotein [2420-3010](Hepatitis C virus genotype 1b (isolate Con1) (HCV))
Gilead Pharmasset
US Patent
Gilead Pharmasset
US Patent
Affinity DataEC50: 1.49E+3nMpH: 7.5 T: 2°CAssay Description:The HCV NS5B reaction was performed in a 20 μL mixture containing varying concentrations of the test compound, 1 μM of all four natural ribonuc...More data for this Ligand-Target Pair
TargetGenome polyprotein [2420-3010](Hepatitis C virus genotype 1b (isolate Con1) (HCV))
Gilead Pharmasset
US Patent
Gilead Pharmasset
US Patent
Affinity DataEC50: 1.55E+3nMpH: 7.5 T: 2°CAssay Description:The HCV NS5B reaction was performed in a 20 μL mixture containing varying concentrations of the test compound, 1 μM of all four natural ribonuc...More data for this Ligand-Target Pair
TargetGenome polyprotein [2420-3010](Hepatitis C virus genotype 1b (isolate BK) (HCV))
Merck Sharp & Dohme
US Patent
Merck Sharp & Dohme
US Patent
Affinity DataEC50: 2.00E+3nMpH: 7.3 T: 2°CAssay Description:The ability of the nucleoside triphosphate derivatives to inhibit the enzymatic activity of the HCV NS5B RNA-dependent RNA polymerase was measured in...More data for this Ligand-Target Pair
TargetGenome polyprotein [2420-3010](Hepatitis C virus genotype 1b (isolate Con1) (HCV))
Gilead Pharmasset
US Patent
Gilead Pharmasset
US Patent
Affinity DataEC50: 3.10E+3nMpH: 7.5 T: 2°CAssay Description:The HCV NS5B reaction was performed in a 20 μL mixture containing varying concentrations of the test compound, 1 μM of all four natural ribonuc...More data for this Ligand-Target Pair
TargetGenome polyprotein [2420-3010](Hepatitis C virus genotype 1b (isolate Con1) (HCV))
Gilead Pharmasset
US Patent
Gilead Pharmasset
US Patent
Affinity DataEC50: 3.50E+3nMT: 2°CAssay Description:To measure cell-based anti-HCV activity of selected compounds of the present invention, replicon cells were seeded at 5000 cells/well in 96-well coll...More data for this Ligand-Target Pair
TargetGenome polyprotein [2420-3010](Hepatitis C virus genotype 1b (isolate Con1) (HCV))
Gilead Pharmasset
US Patent
Gilead Pharmasset
US Patent
Affinity DataEC50: 4.42E+3nMpH: 7.5 T: 2°CAssay Description:The HCV NS5B reaction was performed in a 20 μL mixture containing varying concentrations of the test compound, 1 μM of all four natural ribonuc...More data for this Ligand-Target Pair
TargetGenome polyprotein [2420-3010](Hepatitis C virus genotype 1b (isolate Con1) (HCV))
Gilead Pharmasset
US Patent
Gilead Pharmasset
US Patent
Affinity DataEC50: 4.52E+3nMpH: 7.5 T: 2°CAssay Description:The HCV NS5B reaction was performed in a 20 μL mixture containing varying concentrations of the test compound, 1 μM of all four natural ribonuc...More data for this Ligand-Target Pair
TargetGenome polyprotein [2420-3010](Hepatitis C virus genotype 1b (isolate BK) (HCV))
Merck Sharp & Dohme
US Patent
Merck Sharp & Dohme
US Patent
Affinity DataEC50: 4.55E+3nMpH: 7.3 T: 2°CAssay Description:The ability of the nucleoside triphosphate derivatives to inhibit the enzymatic activity of the HCV NS5B RNA-dependent RNA polymerase was measured in...More data for this Ligand-Target Pair
TargetGenome polyprotein [2420-3010](Hepatitis C virus genotype 1b (isolate BK) (HCV))
Merck Sharp & Dohme
US Patent
Merck Sharp & Dohme
US Patent
Affinity DataEC50: 4.80E+3nMpH: 7.3 T: 2°CAssay Description:The ability of the nucleoside triphosphate derivatives to inhibit the enzymatic activity of the HCV NS5B RNA-dependent RNA polymerase was measured in...More data for this Ligand-Target Pair
TargetGenome polyprotein [2420-3010](Hepatitis C virus genotype 1b (isolate Con1) (HCV))
Gilead Pharmasset
US Patent
Gilead Pharmasset
US Patent
Affinity DataEC50: >8.48E+3nMpH: 7.5 T: 2°CAssay Description:The HCV NS5B reaction was performed in a 20 μL mixture containing varying concentrations of the test compound, 1 μM of all four natural ribonuc...More data for this Ligand-Target Pair
TargetGenome polyprotein [2420-3010](Hepatitis C virus genotype 1b (isolate Con1) (HCV))
Gilead Pharmasset
US Patent
Gilead Pharmasset
US Patent
Affinity DataEC50: 8.65E+3nMpH: 7.5 T: 2°CAssay Description:The HCV NS5B reaction was performed in a 20 μL mixture containing varying concentrations of the test compound, 1 μM of all four natural ribonuc...More data for this Ligand-Target Pair
TargetGenome polyprotein [2420-3010](Hepatitis C virus genotype 1b (isolate BK) (HCV))
Merck Sharp & Dohme
US Patent
Merck Sharp & Dohme
US Patent
Affinity DataEC50: 9.30E+3nMpH: 7.3 T: 2°CAssay Description:The ability of the nucleoside triphosphate derivatives to inhibit the enzymatic activity of the HCV NS5B RNA-dependent RNA polymerase was measured in...More data for this Ligand-Target Pair
TargetGenome polyprotein [2420-3010](Hepatitis C virus genotype 1b (isolate Con1) (HCV))
Gilead Pharmasset
US Patent
Gilead Pharmasset
US Patent
Affinity DataEC50: 9.31E+3nMpH: 7.5 T: 2°CAssay Description:The HCV NS5B reaction was performed in a 20 μL mixture containing varying concentrations of the test compound, 1 μM of all four natural ribonuc...More data for this Ligand-Target Pair
TargetGenome polyprotein [2420-3010](Hepatitis C virus genotype 1b (isolate Con1) (HCV))
Gilead Pharmasset
US Patent
Gilead Pharmasset
US Patent
Affinity DataEC50: 1.00E+4nMT: 2°CAssay Description:To measure cell-based anti-HCV activity of selected compounds of the present invention, replicon cells were seeded at 5000 cells/well in 96-well coll...More data for this Ligand-Target Pair
TargetGenome polyprotein [2420-3010](Hepatitis C virus genotype 1b (isolate Con1) (HCV))
Gilead Pharmasset
US Patent
Gilead Pharmasset
US Patent
Affinity DataEC50: 1.17E+4nMpH: 7.5 T: 2°CAssay Description:The HCV NS5B reaction was performed in a 20 μL mixture containing varying concentrations of the test compound, 1 μM of all four natural ribonuc...More data for this Ligand-Target Pair
TargetGenome polyprotein [2420-3010](Hepatitis C virus genotype 1b (isolate BK) (HCV))
Merck Sharp & Dohme
US Patent
Merck Sharp & Dohme
US Patent
Affinity DataEC50: 1.30E+4nMpH: 7.3 T: 2°CAssay Description:The ability of the nucleoside triphosphate derivatives to inhibit the enzymatic activity of the HCV NS5B RNA-dependent RNA polymerase was measured in...More data for this Ligand-Target Pair
TargetGenome polyprotein [2420-3010](Hepatitis C virus genotype 1b (isolate BK) (HCV))
Merck Sharp & Dohme
US Patent
Merck Sharp & Dohme
US Patent
Affinity DataEC50: 1.40E+4nMpH: 7.3 T: 2°CAssay Description:The ability of the nucleoside triphosphate derivatives to inhibit the enzymatic activity of the HCV NS5B RNA-dependent RNA polymerase was measured in...More data for this Ligand-Target Pair
TargetGenome polyprotein [2420-3010](Hepatitis C virus genotype 1b (isolate Con1) (HCV))
Gilead Pharmasset
US Patent
Gilead Pharmasset
US Patent
Affinity DataEC50: 1.40E+4nMpH: 7.5 T: 2°CAssay Description:The HCV NS5B reaction was performed in a 20 μL mixture containing varying concentrations of the test compound, 1 μM of all four natural ribonuc...More data for this Ligand-Target Pair
TargetGenome polyprotein [2420-3010](Hepatitis C virus genotype 1b (isolate Con1) (HCV))
Gilead Pharmasset
US Patent
Gilead Pharmasset
US Patent
Affinity DataEC50: 1.40E+4nMT: 2°CAssay Description:To measure cell-based anti-HCV activity of selected compounds of the present invention, replicon cells were seeded at 5000 cells/well in 96-well coll...More data for this Ligand-Target Pair
TargetGenome polyprotein [2420-3010](Hepatitis C virus genotype 1b (isolate BK) (HCV))
Merck Sharp & Dohme
US Patent
Merck Sharp & Dohme
US Patent
Affinity DataEC50: 1.50E+4nMpH: 7.3 T: 2°CAssay Description:The ability of the nucleoside triphosphate derivatives to inhibit the enzymatic activity of the HCV NS5B RNA-dependent RNA polymerase was measured in...More data for this Ligand-Target Pair
TargetGenome polyprotein [2420-3010](Hepatitis C virus genotype 1b (isolate BK) (HCV))
Merck Sharp & Dohme
US Patent
Merck Sharp & Dohme
US Patent
Affinity DataEC50: 1.60E+4nMT: 2°CAssay Description:To measure cell-based anti-HCV activity of selected compounds of the present invention, replicon cells were seeded at 5000 cells/well in 96-well coll...More data for this Ligand-Target Pair
TargetGenome polyprotein [2420-3010](Hepatitis C virus genotype 1b (isolate Con1) (HCV))
Gilead Pharmasset
US Patent
Gilead Pharmasset
US Patent
Affinity DataEC50: 1.67E+4nMpH: 7.5 T: 2°CAssay Description:The HCV NS5B reaction was performed in a 20 μL mixture containing varying concentrations of the test compound, 1 μM of all four natural ribonuc...More data for this Ligand-Target Pair
TargetGenome polyprotein [2420-3010](Hepatitis C virus genotype 1b (isolate BK) (HCV))
Merck Sharp & Dohme
US Patent
Merck Sharp & Dohme
US Patent
Affinity DataEC50: 1.80E+4nMpH: 7.3 T: 2°CAssay Description:The ability of the nucleoside triphosphate derivatives to inhibit the enzymatic activity of the HCV NS5B RNA-dependent RNA polymerase was measured in...More data for this Ligand-Target Pair
TargetGenome polyprotein [2420-3010](Hepatitis C virus genotype 1b (isolate Con1) (HCV))
Gilead Pharmasset
US Patent
Gilead Pharmasset
US Patent
Affinity DataEC50: >2.00E+4nMpH: 7.5 T: 2°CAssay Description:The HCV NS5B reaction was performed in a 20 μL mixture containing varying concentrations of the test compound, 1 μM of all four natural ribonuc...More data for this Ligand-Target Pair
TargetGenome polyprotein [2420-3010](Hepatitis C virus genotype 1b (isolate Con1) (HCV))
Gilead Pharmasset
US Patent
Gilead Pharmasset
US Patent
Affinity DataEC50: >2.00E+4nMpH: 7.5 T: 2°CAssay Description:The HCV NS5B reaction was performed in a 20 μL mixture containing varying concentrations of the test compound, 1 μM of all four natural ribonuc...More data for this Ligand-Target Pair
TargetGenome polyprotein [2420-3010](Hepatitis C virus genotype 1b (isolate Con1) (HCV))
Gilead Pharmasset
US Patent
Gilead Pharmasset
US Patent
Affinity DataEC50: >2.00E+4nMpH: 7.5 T: 2°CAssay Description:The HCV NS5B reaction was performed in a 20 μL mixture containing varying concentrations of the test compound, 1 μM of all four natural ribonuc...More data for this Ligand-Target Pair
TargetGenome polyprotein [2420-3010](Hepatitis C virus genotype 1b (isolate Con1) (HCV))
Gilead Pharmasset
US Patent
Gilead Pharmasset
US Patent
Affinity DataEC50: >2.00E+4nMpH: 7.5 T: 2°CAssay Description:The HCV NS5B reaction was performed in a 20 μL mixture containing varying concentrations of the test compound, 1 μM of all four natural ribonuc...More data for this Ligand-Target Pair
TargetGenome polyprotein [2420-3010](Hepatitis C virus genotype 1b (isolate Con1) (HCV))
Gilead Pharmasset
US Patent
Gilead Pharmasset
US Patent
Affinity DataEC50: >2.00E+4nMpH: 7.5 T: 2°CAssay Description:The HCV NS5B reaction was performed in a 20 μL mixture containing varying concentrations of the test compound, 1 μM of all four natural ribonuc...More data for this Ligand-Target Pair
TargetGenome polyprotein [2420-3010](Hepatitis C virus genotype 1b (isolate Con1) (HCV))
Gilead Pharmasset
US Patent
Gilead Pharmasset
US Patent
Affinity DataEC50: >2.00E+4nMpH: 7.5 T: 2°CAssay Description:The HCV NS5B reaction was performed in a 20 μL mixture containing varying concentrations of the test compound, 1 μM of all four natural ribonuc...More data for this Ligand-Target Pair
TargetGenome polyprotein [2420-3010](Hepatitis C virus genotype 1b (isolate BK) (HCV))
Merck Sharp & Dohme
US Patent
Merck Sharp & Dohme
US Patent
Affinity DataEC50: >2.00E+4nMpH: 7.3 T: 2°CAssay Description:The ability of the nucleoside triphosphate derivatives to inhibit the enzymatic activity of the HCV NS5B RNA-dependent RNA polymerase was measured in...More data for this Ligand-Target Pair
TargetGenome polyprotein [2420-3010](Hepatitis C virus genotype 1b (isolate BK) (HCV))
Merck Sharp & Dohme
US Patent
Merck Sharp & Dohme
US Patent
Affinity DataEC50: >2.00E+4nMpH: 7.3 T: 2°CAssay Description:The ability of the nucleoside triphosphate derivatives to inhibit the enzymatic activity of the HCV NS5B RNA-dependent RNA polymerase was measured in...More data for this Ligand-Target Pair
TargetGenome polyprotein [2420-3010](Hepatitis C virus genotype 1b (isolate Con1) (HCV))
Gilead Pharmasset
US Patent
Gilead Pharmasset
US Patent
Affinity DataEC50: 2.06E+4nMpH: 7.5 T: 2°CAssay Description:The HCV NS5B reaction was performed in a 20 μL mixture containing varying concentrations of the test compound, 1 μM of all four natural ribonuc...More data for this Ligand-Target Pair
TargetGenome polyprotein [2420-3010](Hepatitis C virus genotype 1b (isolate BK) (HCV))
Merck Sharp & Dohme
US Patent
Merck Sharp & Dohme
US Patent
Affinity DataEC50: 2.10E+4nMpH: 7.3 T: 2°CAssay Description:The ability of the nucleoside triphosphate derivatives to inhibit the enzymatic activity of the HCV NS5B RNA-dependent RNA polymerase was measured in...More data for this Ligand-Target Pair
TargetGenome polyprotein [2420-3010](Hepatitis C virus genotype 1b (isolate BK) (HCV))
Merck Sharp & Dohme
US Patent
Merck Sharp & Dohme
US Patent
Affinity DataEC50: 2.20E+4nMpH: 7.3 T: 2°CAssay Description:The ability of the nucleoside triphosphate derivatives to inhibit the enzymatic activity of the HCV NS5B RNA-dependent RNA polymerase was measured in...More data for this Ligand-Target Pair
TargetGenome polyprotein [2420-3010](Hepatitis C virus genotype 1b (isolate BK) (HCV))
Merck Sharp & Dohme
US Patent
Merck Sharp & Dohme
US Patent
Affinity DataEC50: 2.30E+4nMpH: 7.3 T: 2°CAssay Description:The ability of the nucleoside triphosphate derivatives to inhibit the enzymatic activity of the HCV NS5B RNA-dependent RNA polymerase was measured in...More data for this Ligand-Target Pair
TargetGenome polyprotein [2420-3010](Hepatitis C virus genotype 1b (isolate BK) (HCV))
Merck Sharp & Dohme
US Patent
Merck Sharp & Dohme
US Patent
Affinity DataEC50: 2.80E+4nMT: 2°CAssay Description:To measure cell-based anti-HCV activity of selected compounds of the present invention, replicon cells were seeded at 5000 cells/well in 96-well coll...More data for this Ligand-Target Pair
TargetGenome polyprotein [2420-3010](Hepatitis C virus genotype 1b (isolate Con1) (HCV))
Gilead Pharmasset
US Patent
Gilead Pharmasset
US Patent
Affinity DataEC50: 2.83E+4nMpH: 7.5 T: 2°CAssay Description:The HCV NS5B reaction was performed in a 20 μL mixture containing varying concentrations of the test compound, 1 μM of all four natural ribonuc...More data for this Ligand-Target Pair
TargetGenome polyprotein [2420-3010](Hepatitis C virus genotype 1b (isolate Con1) (HCV))
Gilead Pharmasset
US Patent
Gilead Pharmasset
US Patent
Affinity DataEC50: 2.85E+4nMpH: 7.5 T: 2°CAssay Description:The HCV NS5B reaction was performed in a 20 μL mixture containing varying concentrations of the test compound, 1 μM of all four natural ribonuc...More data for this Ligand-Target Pair
TargetGenome polyprotein [2420-3010](Hepatitis C virus genotype 1b (isolate BK) (HCV))
Merck Sharp & Dohme
US Patent
Merck Sharp & Dohme
US Patent
Affinity DataEC50: 3.30E+4nMpH: 7.3 T: 2°CAssay Description:The ability of the nucleoside triphosphate derivatives to inhibit the enzymatic activity of the HCV NS5B RNA-dependent RNA polymerase was measured in...More data for this Ligand-Target Pair
TargetGenome polyprotein [2420-3010](Hepatitis C virus genotype 1b (isolate BK) (HCV))
Merck Sharp & Dohme
US Patent
Merck Sharp & Dohme
US Patent
Affinity DataEC50: 3.70E+4nMpH: 7.3 T: 2°CAssay Description:The ability of the nucleoside triphosphate derivatives to inhibit the enzymatic activity of the HCV NS5B RNA-dependent RNA polymerase was measured in...More data for this Ligand-Target Pair
TargetGenome polyprotein [2420-3010](Hepatitis C virus genotype 1b (isolate Con1) (HCV))
Gilead Pharmasset
US Patent
Gilead Pharmasset
US Patent
Affinity DataEC50: 3.80E+4nMT: 2°CAssay Description:To measure cell-based anti-HCV activity of selected compounds of the present invention, replicon cells were seeded at 5000 cells/well in 96-well coll...More data for this Ligand-Target Pair
TargetGenome polyprotein [2420-3010](Hepatitis C virus genotype 1b (isolate BK) (HCV))
Merck Sharp & Dohme
US Patent
Merck Sharp & Dohme
US Patent
Affinity DataEC50: 3.90E+4nMpH: 7.3 T: 2°CAssay Description:The ability of the nucleoside triphosphate derivatives to inhibit the enzymatic activity of the HCV NS5B RNA-dependent RNA polymerase was measured in...More data for this Ligand-Target Pair